iProXProteomicsGuowei ShiHomo Sapienshttp://www.iprox.org/page/project.html?id=IPX0010314000dr.sgw@189.cnThe Fifth People's Hospital of Shanghai, Fudan UniversityiProX<h4>Purpose</h4>Vaccinia-related kinase 1 (VRK1) is a serine-threonine kinase involved in the proliferation and migration of various cancer cells. However, its role in prostate cancer (PCa), particularly in the development of therapeutic resistance, remains unclear.<h4>Methods</h4>We established an androgen-independent PCa cell line derived from LNCaP prostate cancer cells and conducted transcriptome and proteome sequencing together with bioinformatic analyses of large clinical sample databases to investigate the potential role of VRK1 in PCa progression. The correlation between VRK1 and androgen receptor (AR) signaling was evaluated under simulated clinical treatment conditions. The effects of VRK1 on cell proliferation were assessed in vitro and in vivo using Cell Counting Kit-8 and colony formation assays. Additionally, proteome and transcriptome sequencing, combined with rescue experiments were performed to explore VRK1-regulated signaling pathways related to cell proliferation and therapeutic resistance.<h4>Results</h4>VRK1 expression was elevated during the progression of androgen-dependent prostate cancer to castration-resistant prostate cancer under therapeutic conditions, and high VRK1 expression was associated with a poor prognosis in patients with PCa. VRK1 was regulated by AR signaling, and its silencing suppressed PCa cell proliferation both in vitro and in vivo. VRK1 drove cell proliferation and therapeutic resistance in PCa by modulating yes-associated protein 1 (YAP1).<h4>Conclusions</h4>VRK1 serves as a prognostic marker in PCa, regulated by AR signaling. VRK1 depletion inhibited cell proliferation both in vitro and in vivo, while elevated VRK1 upregulated YAP1, promoting cell proliferation and therapeutic resistance.Elevated VRK1 levels after androgen deprivation therapy promote prostate cancer progression by upregulating YAP1 expression.Meng Yibo Y, Ge Jianchao J, Zhou Cheng C, Ma Hangbin H, Chen Chenchen C, Zhou Yinghao Y, Hu Xuetao X, Xu Yaozong Y, Wang Xilong X, Shi Guowei G, Yu Wandong W, Zhang Jun Jhereditary prostate cancer, cancer of the prostate, Plays, Prostate Neoplasms, Drug resistance, Neoplasms, 51PK, postnatal development, drug susceptibility/resistance, familial, growth and development, Prostate Cancers., Concept, development, vaccinia-related kinase 1, PCH1A, Role Concept, VRK1, Playthings and Play, Roles, Prostatic Cancer, Role, Resistance, Neoplasm, Prostatic Cancers, Plaything, Concepts, NOS, PCH1, Cancer of Prostate, drug resistance, Toy, Playthings, growth pattern, non-developmental growth, serine/threonine-protein kinase 51PK, postnatal growth, response to drug, Toys, Cancers, cancer of prostate, Prostate Neoplasm, Drug, Prostatic Neoplasm, Puppets, Cancer of the Prostate, Role Concepts, Play, Prostatic, prostate cancer, PC, growth, Prostate Cancer, Puppet, Prostate, Cancerhereditary prostate cancer, study, cancer of the prostate, biological function, single-organism developmental process, Prostate Neoplasms, Neoplasms, 51PK, serine/threonine-protein kinase 51PK, postnatal development, postnatal growth, familial, growth and development, Cancers, cancer of prostate, Prostate Neoplasm, Prostate Cancers., development, vaccinia-related kinase 1, PCH1A, Prostatic Neoplasm, Cancer of the Prostate, VRK1, Prostatic Cancer, Neoplasm, Prostatic Cancers, Prostatic, prostate cancer, PC, NOS, PCH1, Cancer of Prostate, growth, Prostate Cancer, Prostate, Cancerandrogeno, YAP65, androgens, single-organism developmental process, Compounds, acetylglucosaminyltransferase-like protein, Vaccinia-related kinase 1, Serine-Threonine Protein Kinases, postnatal development, Mbp1, Receptors, Gene Expression Profile, CaP cell line, Yap65, growth and development, Profiles, Xkl-1, Tumor, Androgens Receptors, androgene, Cell Growth in Number, Molecular Biologies, DHTR, dmTAF[[II]]230, vaccinia-related kinase 1, Serine-Threonine Kinase, Techniques, KL receptor activity, Gsfsco1, Bio Informatics, Roles, Method, Cell Number Growth, SCO5, Concepts, Protein Kinases, SCO1, Kinase, 5, PCH1, myd, Gsfsow3, Effect, Gsfsco5, Benson syndrome, SOW3, multicellular organismal biosynthetic process, Gonadectomies, Testosterone Receptor, amyloidosis, single-organism biosynthetic process, Growth, Pca-1, Prognoses, like-acetylglucosaminyltransferase, TFIID TAF250, Yap, YAP, Biology, cel, Mbp-1, clinical_treatment, twy, procedures, W, Serine Threonine Protein Kinase, Bio-Informatic, Stanolone Receptors, Signatures, Computational, Prostatic Neoplasm, Cancer of the Prostate, Methodological Studies, Dihydrotestosterone Receptors, malignant neoplasm, Expression Signature, Bio-Informatics, sample, Role Concepts, Protein-Serine-Threonine, Therapies, Transcriptomes, Protein Serine Kinase, Testosterone, Bs, Malignancies, Sl, Protein-Serine-Threonine Kinase, Computational Molecular Biologies, single organism signaling, Tumors, Therapy, LNCaP, cancer of the prostate, dTAF[[II]]230, Protein-Serine-Threonine Kinases, gyltl1b-b, Pdnp1, Androgen Receptor Agonist, CaP cell, Expression Profiles, Biologies, familial, arteria cerebri communicans posterior, TAF200, Tr-kit, familial cutaneous lichen, Test, Receptor Agonists, Procedure, Androgen Effects, TAFII-250, TAF250/230, Computational Molecular, Gene Expression, Androgen Effect, LNCAP, PBT, Androgen, 4833416E15Rik, TAFII250, Benign, Role Concept, C76301, MDDGA6, Expression Signatures, mKIAA0609, Computational Molecular Biology, Pca, PCA, Role, POSTERIOR, kl1-A, Cellular, NOS, KIT, Serine Threonine Kinases, Serine-Threonine, KIAA0609, AXPC1, Expression Profile, acetylglucosaminyltransferase-like 1A, Transcriptome Profiles, PCS, fg, tyrosine-protein kinase Kit, Protein Serine Threonine Kinases, Stanolone, pbt, YAP2, gyltl1b, 5 alpha-Dihydrotestosterone, Factors, Bioinformatic, In Vitro, Tests, Prognostic, mdc1d, Dihydrotestosterone, Anaphylaxis, Benign Neoplasms, PCa cell line, Protein-Threonine, androgenes, Methodological, kit, CG17603, Serine Threonine Kinase, cancer of prostate, Methodological Study, LARGE_HUMAN, TAF[[II]], Yes-associated protein YAP65 homolog, Treatments, Androgenic Compounds, Malignant Neoplasms, MDC1D, Protein Threonine Kinase, Agents, enr, Taf250, Patient, Serine|threonine-protein kinase 51PK, Proliferation, SR3-5, Cell Number, Androgen Receptor, PC-1, Protein Kinase, Ly-41, Proteomes, Prostate, TAF230, krk1, Prognostic Factor, Passive, CD203c, d230, NPP1, Procedures, Prostate Neoplasms, In Vitro as Topic, Testings, Effects, Transcriptome Profile, Neoplasms, prostate gland cancer cell line, Benign Neoplasm, Protein Serine-Threonine, LNCAP cell, SCF receptor activity, Gene, dTAFII250, Prognostic Factors, Receptor Agonist, Malignant, EfW1, LARGE1, froggy, Gyltl1a, 5 alpha Dihydrotestosterone Receptor, In Vitro Testing, PCH1A, Protein-Serine Kinase, scfr, VRK1, dmTAF1, Taf230, Prostatic Cancers, Studies, Number Growth, Cancer of Prostate, Agonists, SCFR, Technique, In Vitro Tests, Prostate Cancers, TAF250, Npps, Passive Cutaneous, FLVCR, Agonist, Taf200, Fdc, In, Serine-Threonine Kinases, dTAF[[II]]250, Malignancy, cell, MDDGB6, Profile, biparietal Alzheimer disease, Taf1p, Treatments., LARGE, lichen amyloidosis, Neoplasias, Study, BPFD#36, dTAF250, PCa cell, cell proliferation, Serine Threonine Protein Kinases, Clients, Protein Serine Threonine Kinase, Prostatic, MFSD7B, Yki, YKI, Androgen Receptor Agonists, Androgenic, TAF, Yorkie, Protein yorkie homolog, Cancer, hereditary prostate cancer, Multiplication, proto-oncogene c-Kit, Molecular Biology, COB1, TAF[[II]]250, Transcriptome, Cellular Proliferation, Malignant Neoplasm, 51PK, Protein-Threonine Kinase, total expressed protein, l(3)84Ab, BG:DS00004.13, Factor, androgenos, Client, Cell, Bioinformatics, Stanolone Receptor, Cutaneous Anaphylaxis, Testing, Concept, dTAF230, development, M6S1, 2.7.11.1, In Vitro Test, MT, KIT ligand receptor activity, AI428932, Androgene, p230, Prostatic Cancer, Gene Expression Signatures, clinical treatment, Neoplasm, In Vitro Testings, Protein-Serine, TAF[[II]]250/230, Androgens, TFIID, Threonine Kinase, Gene Expression Signature, techniques, Vitro Testing, Androgen Receptors, SNQ3, XKrk1, 5 alpha-Dihydrotestosterone Receptor, Gonadectomy, Taf[[II]]250, Serine-Threonine Protein Kinase, alpha-Dihydrotestosterone Receptor, c-KIT, Castrations, primary cancer, Yes-associated protein 1, Serine Kinase, TAF[[II]]230, Kinases, serine/threonine-protein kinase 51PK, postnatal growth, choanal atresia, Androgenic Agents, TAF[II]250, Cancers, AI325207, CD117, malignant tumor, sample population, Prostate Neoplasm, prostate tumor cell line, c-kit, DmelCG17603, prostate carcinoma cell line, like-glycosyltransferase, signalling process, Therapeutic, C-Kit, PCARP, Gene Expression Profiles, Ssm, Cell Multiplication, In Vitro Technique, xkl-1, NR3C4, prostate cancer, PC, Treatment, Receptor, PAR1, E-NPP1, ttw, Signature, Prostate Cancer, growth, Neoplasia, methodology, glycosyltransferase-like protein LARGE1, TAF1androgeno, Therapy, hereditary prostate cancer, YAP65, androgens, cancer of the prostate, COB1, SNQ3., Prostate Neoplasms, Effects, Compounds, Androgen Receptor Agonist, Neoplasms, 51PK, familial, Yap65, Receptor Agonists, Receptor Agonist, Androgen Effects, androgene, androgenos, vaccinia-related kinase 1, PCH1A, Androgen Effect, Androgen, VRK1, Androgene, Prostatic Cancer, Neoplasm, Prostatic Cancers, NOS, PCH1, Agonists, Cancer of Prostate, Effect, Prostate Cancers, treatment, Agonist, YAP2, Yap, YAP, serine/threonine-protein kinase 51PK, Androgenic Agents, androgenes, Cancers, AI325207, cancer of prostate, Treatments, Androgenic Compounds, Prostate Neoplasm, Prostatic Neoplasm, Cancer of the Prostate, Agents, Therapeutic, disease management, Therapies, Androgen Receptor, Prostatic, prostate cancer, Treatment, PC, PAR1, Yki, YKI, Androgen Receptor Agonists, Androgenic, Prostate Cancer, Yorkie, Prostate, CancerfalseStudy of biological function of VRK1 in the development and progress of prostate cancerVRK1 plays a significant role in the growth and drug resistance of prostate cancer.Fri Nov 22 00:00:00 GMT 2024PXD058205960640111564